Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA<sub>2</sub>DS<sub>2</sub>-VASc Score 0–1: A Korean Multi-Center Cohort

Jung, Moonki; Byeon, Kyeongmin; Kang, Kyungkeun; Park, Yae Min; Hwang, You Mi; Lee, Sung Ho; Jin, Eun‐Sun; Roh, Seung Young; Kim, Jin-Seok; Ahn, Jinhee; Lee, So‐Ryoung; Choi, Eue Keun; Ahn, Min Soo; Lee, Eun Mi; Park, Hwan-Cheol; Lee, Ki Hong; Kim, Min; Choi, Joon-Hyouk; Ko, Jum Suk; Kim, Jin Bae; Kim, Hyunmin; Lip, Gregory Y. H.; Shin, Seung Yong

doi:10.3349/ymj.2022.0157

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Creatinine clearance was calculated using the Cockcroft–Gault formula, 17 and the LA dimension was measured in the M‐mode of the parasternal long axis view of transthoracic echocardiography 18 . According to the stratification method of thromboembolic risk in a previous study, the patients were categorized into two groups according to ABCD score and analyzed as follows: (1) ABCD score 0 and (2) ABCD score ≥1 19 . Patients enrolled in the study were further categorized based on types of ATT as follows: (1) aspirin or P2Y12 inhibitor (clopidogrel) as a single antiplatelet (SAPT) therapy, (2) vitamin K antagonist (VKA) therapy, and (3) non‐vitamin K antagonist oral anticoagulant (NOAC) therapy (apixaban, dabigatran, rivaroxaban, or edoxaban).…”

Section: Methodsmentioning

confidence: 99%

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Jung

Byeon

Kang

et al. 2023

Journal of Arrhythmia

Self Cite

View full text Add to dashboard Cite

Background The balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non‐gender CHA2DS2‐VASc scores 0–1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non‐gender CHA2DS2‐VASc scores 0–1. Methods This multi‐center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non‐VKA oral anticoagulant (NOAC) in non‐gender CHA2DS2‐VASc score 0–1 and further stratified by biomarker‐based ABCD score (Age [≥60 years], B‐type natriuretic peptide [BNP] or N‐terminal pro‐BNP [≥300 pg/mL], creatinine clearance [<50 mL/min], and dimension of the left atrium [≥45 mm]). The primary outcome was the NCB of ATT, including composite thrombotic events (ischemic stroke, systemic embolism, and myocardial infarction) and major bleeding events. Results We included 2465 patients (age 56.2 ± 9.5 years; female 27.0%) followed‐up for 4.0 ± 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37–4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56–5.40) in ABCD score ≥1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0). Conclusions In the Korean AF cohort at non‐gender CHA2DS2‐VASc scores 0–1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score ≥1.

show abstract

Section: Methodsmentioning

confidence: 99%

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Jung

Byeon

Kang

et al. 2023

Journal of Arrhythmia

Self Cite

View full text Add to dashboard Cite

show abstract

“…9 For the clinical application of biomarkers, the refinement of further risk stratification of clinical outcomes, particularly for those initially classified as low-risk with a nonsex CHA 2 DS 2 -VASc score of 0 or 1, would be noteworthy. 10 , 11 Therefore, the use of biomarkers may uncover truly low-risk patients with AF among those previously identified as at low risk of stroke.…”

mentioning

confidence: 99%

Coagulation Biomarkers for Predicting Clinical Outcomes Among Patients With Atrial Fibrillation

Choi,

Kwon

2023

JACC: Asia

Self Cite

View full text Add to dashboard Cite

Comparison of a Polysaccharide Hemostatic Powder and Conventional Therapy for Peptic Ulcer Bleeding

Jung¹,

Park²,

Choi³

et al. 2023

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA₂DS₂-VASc Score 0–1: A Korean Multi-Center Cohort

Cited by 3 publications

References 46 publications

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Coagulation Biomarkers for Predicting Clinical Outcomes Among Patients With Atrial Fibrillation

Comparison of a Polysaccharide Hemostatic Powder and Conventional Therapy for Peptic Ulcer Bleeding

Contact Info

Product

Resources

About

Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0–1: A Korean Multi-Center Cohort

Cited by 3 publications

References 46 publications

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Coagulation Biomarkers for Predicting Clinical Outcomes Among Patients With Atrial Fibrillation

Comparison of a Polysaccharide Hemostatic Powder and Conventional Therapy for Peptic Ulcer Bleeding

Contact Info

Product

Resources

About

Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA₂DS₂-VASc Score 0–1: A Korean Multi-Center Cohort